Brain Tumor Drugs Market was estimated at US$ 2.9 billion in 2022 and is expected to reach US$ 5.73 billion by 2030. and is anticipated to increase at a CAGR of 8.9% predicted for the forecast period of 2022-2030.
The term "brain Tumor drugs" refers to a broad category of pharmacological formulations used to treat various forms of brain cancer. The rising prevalence of brain Tumors throughout the world has led to an increase in demand for this class of medications. The development of innovative treatment paradigms that take use of each patient's particular genetic composition, such as targeted medicines and personalised medicine, has been a major market growth driver. Both patient survival rates and quality of life are increasing as a result of this transition towards a more personalised approach to therapy. Additionally, the industry is benefiting from increasing funding for the study and creation of novel, more potent brain Tumor treatments. The lack of qualified neuro-oncologists and strict regulatory standards, for example, might pose obstacles to the market's expansion. But because to ongoing improvements in medical technology, a focus on cancer research, and greater financing from both public and commercial sources, the outlook is still mainly optimistic. The market for drugs for brain Tumors has been shaped by a number of notable phenomena. As invasive procedures become far less necessary thanks to non-invasive medication delivery methods, patients experience less stress and have more manageable treatment regimens. Precision medicine is having a significant impact by enabling the development of specialised medicines that increase efficacy and reduce negative effects. This is made possible by accurate genetic profiling. The advent of cutting-edge treatments like gene and immunotherapy is opening up new avenues for the treatment of brain Tumors. The effectiveness and safety of medications for brain Tumors are also being improved through the application of artificial intelligence (AI) and machine learning in drug development and testing procedures.
DRIVERS
Brain Tumor incidence is rising.
Research and development improvements& Increasing need for Specialized treatments.
The market for drugs to treat brain tumors is significantly fueled by the growing incidence of brain tumors throughout the world. The frequency of brain tumors is rising due to a number of variables, including an ageing population, exposure to environmental risk factors, and improved diagnostic methods. Potential therapeutic targets have been found as a result of developments in our knowledge of the molecular processes behind brain tumorigenesis. The result is the creation of innovative brain tumor drugs that specifically target the underlying molecular changes in brain tumor cells. This motivates research and development activities. Brain tumor therapy is increasingly relying on targeted medicines, such as precision medicine techniques. The choice of tailored therapy is made possible by the use of companion diagnostics to detect certain genetic abnormalities or biomarkers in brain tumors, which is anticipated to lead to market growth.
RESTRAIN
High expenses for development& less available treatments.
Preclinical and clinical studies, as well as other research and development expenses, are expensive when creating medications to treat brain tumors. Pharmaceutical businesses have financial difficulties due to the high cost of medication research and the possibility of clinical trial failures, which might impede the market's expansion. There are several medical problems associated with treating brain tumors, especially specific forms like glioblastoma. The intricacy of brain tumors and the scarcity of viable treatments make it challenging to create new medications. The absence of ground-breaking treatments may limit market expansion.
OPPORTUNITY
The use of companion diagnostics and personalised medicine with new methods of immunotherapy.
Companion diagnostics make it possible to use personalized medicine techniques to create treatment plans that are unique to each patient. The development of complementary diagnostics that spot biomarkers or genetic changes in brain tumors can help doctors choose more effective targeted medicines. Research is still being done to determine the potential of immunotherapy for treating brain tumors, which has shown promise in a number of cancer types. Combination therapy and the development of immunotherapeutic medicines may open up new possibilities for the treatment of brain tumors.
CHALLENGES
Penetration of the blood-brain barrier (BBB) & Differentiation of brain Tumors.
Regulatory and payment difficulties.
Drug delivery to the brain is complicated by the BBB because it prevents many therapeutic substances from passing through. It is still difficult to create medications that can successfully pass across the BBB and target brain cancer cells. High heterogeneity can be seen in brain cancers, both within and within various tumor forms. The development of medications that successfully target all subtypes and genetic mutations is difficult due to the complexity and variety of brain tumors. The regulatory procedure for authorizing drugs for brain tumors may be difficult and drawn out. The market availability and cost of therapies for brain tumors may also be hampered by varying reimbursement and coverage regulations.
We continually study the reports and updated news in light of the ongoing political and economic unpredictability caused by the conflict in Russia and Ukraine. The Ukrainian healthcare system is dealing with a variety of difficulties as a result of the Russian invasion, which began on 24 February 2022. Many healthcare facilities have been damaged, and the availability of others is sometimes constrained owing to a shortage of trained medical personnel. Cancer medicines are only one example of a service that has been severely affected. As a result of difficulties with the implementation of their long-term medicines, millions of Ukrainians with chronic diseases also suffer. Drug availability is especially scarce in areas that are inhabited. National figures show that as of August 18, 2022, 48 pharmacies in Eastern Ukraine were entirely destroyed and around 508 had minor damage. Additionally, the invaders have been preventing the Ukrainian government or other nations from sending humanitarian relief to these districts.
IMPACT OF ONGOING RECESSION
Over the past two years, prices have increased significantly as a result of the high inflation rates in industrialised nations throughout the world. It is anticipated that the aggregate buying power would considerably affect emerging economies and is thought to be beneficial in many ways. The paper reveals how high inflation affects the long-term health of the global economy and offers information on the fiscal measures that may be taken to lessen its short-term effects on demand/supply, cash flow, and currency exchange. Given the associated effects of cost-push and demand-pull inflation, the Brain Tumor Drugs Market research projects a high rate of inflation.
KEY MARKET SEGMENTS
By Therapy Types
Immunotherapy
Chemotherapy
Targeted Therapy
Other
By Indication
Glioblastoma
Meningioma
Pituitary Tumors
Other
By Distribution Channels
Retail Pharmacy
Hospital Pharmacy
Other
.png)
North America
USA
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Rest of Europe
Asia-Pacific
Japan
South Korea
China
India
Australia
Rest of Asia-Pacific
The Middle East & Africa
Israel
UAE
South Africa
Rest of the Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin American
North America:
In 2015, North America accounted for more than 46.0% of the global market for brain Tumor diagnostic and treatment. Rendering elements are undoubtedly impacted by a developed healthcare system, more healthcare spending per person, and relatively better knowledge of cutting-edge technology.
Europe:
Due to the rising incidence of malignant malignancies in nations like the U.K., Europe is anticipated to have a sizable impact on this market throughout the projected period. For instance, according to data from the UK's Office for National Statistics, there were around 10,984 new cases reported in the area in 2014.
The Major Key players are AbbVie Inc., Amgen Inc., AstraZeneca, Bayer AG, Bristol-Myers Squibb, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Ipsen Biopharmaceuticals, Inc., Johnson & Johnson, Merck & Co, Inc., Novartis AG, Pfizer Inc, and Sanofi SA, and others.
Pfizer Inc:
Acquired Trillium Therapeutics is an immune-oncology business in the clinical stages that focuses largely on creating cutting-edge treatments for the treatment of cancer.
F. Hoffmann-La Roche Ltd
Rozlytrek (entrectinib), a medication, has been given the green light by Health Canada for the treatment of adult patients with locally advanced or metastatic extracranial solid Tumors, including brain metastases.
| Report Attributes | Details |
| Market Size in 2022 | US$ 2.9 Bn |
| Market Size by 2030 | US$ 5.73 Bn |
| CAGR | CAGR of 8.9% From 2023 to 2030 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Historical Data | 2020-2021 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Therapy Types (Immunotherapy, Chemotherapy, Targeted Therapy, Other) • By Indication (Glioblastoma, Meningioma, Pituitary Tumors, Other) • By Distribution Channels (Retail Pharmacy, Hospital Pharmacy, Other) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | AbbVie Inc., Amgen Inc., AstraZeneca, Bayer AG, Bristol-Myers Squibb, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Ipsen Biopharmaceuticals, Inc., Johnson & Johnson, Merck & Co, Inc., Novartis AG, Pfizer Inc, and Sanofi SA, and others. |
| Key Drivers | • Brain Tumor incidence is rising. • Research and development improvements& Increasing need for Specialized treatments. |
| Market Opportunities | • The use of companion diagnostics and personalised medicine with new methods of immunotherapy. |
Ans: The CAGR of 8.9% for the forecast period of 2022-2030.
Ans: The projected market size of Brain Tumor Drugs Market US$ 2.9 billion in 2022 and is expected to reach US$ 5.73 billion by 2030.
Ans: The Major Key players are AbbVie Inc., Amgen Inc., AstraZeneca, Bayer AG, Bristol-Myers Squibb, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Ipsen Biopharmaceuticals, Inc., Johnson & Johnson, Merck & Co, Inc., Novartis AG, Pfizer Inc, and Sanofi SA, and others.
Ans: The chemotherapy category will dominate the market in terms of therapy.
Ans: The main types of brain Tumors are astrocytoma, glioblastoma, oligodendroglioma and ependymoma.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of the Ukraine- Russia war
4.2 Impact of ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Brain Tumor Drugs Market By Therapy Types
8.1 Immunotherapy
8.2 Chemotherapy
8.3 Targeted Therapy
8.4 Other
9. Brain Tumor Drugs Market By Indication
9.1 Glioblastoma
9.2 Meningioma
9.3 Pituitary Tumors
9.4 Other
10. Brain Tumor Drugs Market By Distribution Channels
10.1 Retail Pharmacy
10.2 Hospital Pharmacy
10.3 Other
11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 North America Brain Tumor Drugs Market by country
11.2.2North America Brain Tumor Drugs Market By Therapy Types
11.2.3 North America Brain Tumor Drugs Market By Indication
11.2.4 North America Brain Tumor Drugs Market by Distribution of channel
11.2.5 USA
11.2.5.1 USA Brain Tumor Drugs Market By Therapy Types
11.2.5.2 USA Brain Tumor Drugs Market by Indication
11.2.5.3 USA Brain Tumor Drugs Market by Distribution of channel
11.2.6 Canada
11.2.6.1 Canada Brain Tumor Drugs Market By Therapy Types
11.2.6.2 Canada Brain Tumor Drugs Market By Indication
11.2.6.3 Canada Brain Tumor Drugs Market By Distribution Channelss
11.2.7 Mexico
11.2.7.1 Mexico Brain Tumor Drugs Market By Therapy Types
11.2.7.2 Mexico Brain Tumor Drugs Market By Indication
11.2.7.3 Mexico Brain Tumor Drugs Market By Distribution Channelss
11.8 Europe
11.8.1 Europe Brain Tumor Drugs Market by country
11.8.2 Europe Brain Tumor Drugs Market By Therapy Types
11.8.3 Europe Brain Tumor Drugs Market By Indication
11.8.4 Europe Brain Tumor Drugs Market By Distribution Channelss
11.8.6 Germany
11.8.6.1 Germany Brain Tumor Drugs Market By Therapy Types
11.8.6.2 Germany Brain Tumor Drugs Market By Indication
11.8.6.3 Germany Brain Tumor Drugs Market By Distribution Channelss
11.8.7 UK
11.8.7.1 UK Brain Tumor Drugs Market By Therapy Types
11.8.7.2 UK Brain Tumor Drugs Market By Indication
11.8.7.3 UK Brain Tumor Drugs Market By Distribution Channelss
11.8.8 France
11.8.8.1 France Brain Tumor Drugs Market By Therapy Types
11.8.8.2 France Brain Tumor Drugs Market By Indication
11.8.8.3 France Brain Tumor Drugs Market By Distribution Channelss
11.9.9 Italy
11.3.9.1 Italy Brain Tumor Drugs Market By Therapy Types
11.3.9.2 Italy Brain Tumor Drugs Market By Indication
11.3.9.3 Italy Brain Tumor Drugs Market By Distribution Channelss
11.3.10 Spain
11.3.10.1 Spain Brain Tumor Drugs Market By Therapy Types
11.3.10.2 Spain Brain Tumor Drugs Market By Indication
11.3.10.3 Spain Brain Tumor Drugs Market By Distribution Channelss
11.3.11 The Netherlands
11.3.11.1 Netherlands Brain Tumor Drugs Market By Therapy Types
11.3.11.2 Netherlands Brain Tumor Drugs Market By Indication
11.3.11.3 Netherlands Brain Tumor Drugs Market By Distribution Channelss
11.3.11 Rest of Europe
11.3.11.1 Rest of Europe Brain Tumor Drugs Market By Therapy Types
11.3.11.2 Rest of Europe Brain Tumor Drugs Market By Indication
11.3.11.3 Rest of Europe Brain Tumor Drugs Market By Distribution Channelss
11.4 Asia-Pacific
11.4.1 Asia Pacific Brain Tumor Drugs Market by country
11.4.2 Asia Pacific Brain Tumor Drugs Market By Therapy Types
11.4.3 Asia Pacific Brain Tumor Drugs Market By Indication
11.4.4Asia Pacific Brain Tumor Drugs Market By Distribution Channelss
11.4.6 Japan
11.4.6.1 Japan Brain Tumor Drugs Market By Therapy Types
11.4.6.2 Japan Brain Tumor Drugs Market By Indication
11.4.6.3 Japan Brain Tumor Drugs Market By Distribution Channelss
11.4.7 South Korea
11.4.7.1 South Korea Brain Tumor Drugs Market By Therapy Types
11.4.7.2 South Korea Brain Tumor Drugs Market By Indication
11.4.7.3 South Korea Brain Tumor Drugs Market By Distribution Channelss
11.4.8 China
11.4.8.1 China Brain Tumor Drugs Market By Therapy Types
11.4.8.2 China Brain Tumor Drugs Market By Indication
11.4.8.3 China Brain Tumor Drugs Market By Distribution Channelss
11.4.9 India
11.4.9.1 India Brain Tumor Drugs Market By Therapy Types
11.4.9.2 India Brain Tumor Drugs Market By Indication
11.4.9.3 India Brain Tumor Drugs Market By Distribution Channelss
11.4.10 Australia
11.4.10.1 Australia Brain Tumor Drugs Market By Therapy Types
11.4.10.2 Australia Brain Tumor Drugs Market By Indication
11.4.10.3 Australia Brain Tumor Drugs Market By Distribution Channelss
11.4.11 Rest of Asia-Pacific
11.4.11.1 APAC Brain Tumor Drugs Market By Therapy Types
11.4.11.2 APAC Brain Tumor Drugs Market By Indication
11.4.11.3 APAC Brain Tumor Drugs Market By Distribution Channelss
11.5 The Middle East & Africa
11.5.1 The Middle East & Africa Brain Tumor Drugs Market by country
11.5.2 The Middle East & Africa Brain Tumor Drugs Market By Therapy Types
11.5.3 The Middle East & Africa Brain Tumor Drugs Market By Indication
11.5.4The Middle East & Africa Brain Tumor Drugs Market By Distribution Channelss
11.5.6 Israel
11.5.6.1 Israel Brain Tumor Drugs Market By Therapy Types
11.5.6.2 Israel Brain Tumor Drugs Market by Distribution of channel
11.5.6.3 Israel Brain Tumor Drugs Market By Indication
11.5.7 UAE11.5.7.1 UAE Brain Tumor Drugs Market By Therapy Types
11.5.7.2 UAE Brain Tumor Drugs Market By Indication
11.5.7.3 UAE Brain Tumor Drugs Market By Distribution Channelss
11.5.8 South Africa
11.5.8.1 South Africa Brain Tumor Drugs Market By Therapy Types
11.5.8.2 South Africa Brain Tumor Drugs Market By Indication
11.5.8.3 South Africa Brain Tumor Drugs Market By Distribution Channelss
11.5.9 Rest of Middle East & Africa
11.5.9.1 Rest of Middle East & Asia Brain Tumor Drugs Market By Therapy Types
11.5.9.2 Rest of Middle East & Asia Brain Tumor Drugs Market By Indication
11.5.9.3 Rest of Middle East & Asia Brain Tumor Drugs Market By Distribution Channelss
11.6 Latin America
11.6.1 Latin America Brain Tumor Drugs Market by country
11.6.2 Latin America Brain Tumor Drugs Market By Therapy Types
11.6.3 Latin America Brain Tumor Drugs Market By Indication
11.6.4 Latin America Brain Tumor Drugs Market By Distribution Channelss
11.6.6 Brazil11.6.6.1 Brazil Brain Tumor Drugs Market By Therapy Types
11.6.6.2 Brazil Africa Brain Tumor Drugs Market By Indication
11.6.6.3Brazil Brain Tumor Drugs Market By Distribution Channelss
11.6.7 Argentina
11.6.7.1 Argentina Brain Tumor Drugs Market By Therapy Types
11.6.7.2 Argentina Brain Tumor Drugs Market By Indication
11.6.7.3 Argentina Brain Tumor Drugs Market By Distribution Channelss
11.6.8 Rest of Latin America
11.6.8.1 Rest of Latin America Brain Tumor Drugs Market By Therapy Types
11.6.8.2 Rest of Latin America Brain Tumor Drugs Market By Indication
11.6.8.3 Rest of Latin America Brain Tumor Drugs Market By Distribution Channels
12 Company profile
12.1 AbbVie Inc.,
12.1.1 Market Overview
12.1.2 Financials
12.1.3 Treatment/Services/Offerings
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 Amgen Inc.,
12.2.1 Market Overview
12.2.2 Financials
12.2.3 Treatment/Services/Offerings
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 AstraZeneca,
12.3.1 Market Overview
12.3.2 Financials
12.3.3 Treatment/Services/Offerings
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Bayer AG,
12.4.1 Market Overview
12.4.2 Financials
12.4.3 Treatment/Services/Offerings
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 Bristol-Myers Squibb,
12.5.1 Market Overview
12.5.2 Financials
12.5.3 Treatment/Services/Offerings
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 Eisai Co.
12.6.1 Market Overview
12.6.2 Financials
12.6.3 Treatment/Services/Offerings
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 Eli Lilly and Company,
12.7.1 Market Overview
12.7.2 Financials
12.7.3 Treatment/Services/Offerings
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 F. Hoffmann-La Roche Ltd,
12.8.2 Financials
12.8.3 Treatment/Services/Offerings
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 Majestic Mirror & Frame
12.9.1 Market Overview
12.9.2 Financials
12.9.3 Treatment/Services/Offerings
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10. Ipsen Biopharmaceuticals, Inc.,
12.10.1 Market Overview
12.10.2 Financials
12.10.3 Treatment/Services/Offerings
12.10.4 SWOT Analysis
12.10.5 The SNS View
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share analysis
13.3 Recent Developments
14 Use Case and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Video Laryngoscope Market size was USD 488.73 Million in 2022 and is expected to Reach USD 1874.76 Million by 2030 and grow at a CAGR of 18.3% over the forecast period of 2023-2030.
The Opioid Use Disorder Market size was valued at USD 3.13 billion in 2022 and it is expected to be worth around USD 6.15 billion by 2030 growing at a remarkable GAGR of 8.8% over the forecast period 2023-2030.
The Oxytocic Pharmaceuticals Market Size was valued at USD 110.26 billion in 2022 and is expected to reach USD 204.09 billion by 2030, and grow at a CAGR of 8% over the forecast period 2023-2030.
The Echocardiography Market was estimated at US$ 2.01 billion in 2023 and is expected to reach US$ 3.54 billion by 2031 and is anticipated to increase at a CAGR of 7.21% predicted for the forecast period of 2024-2031.
The Consumer Healthcare market size was valued at USD 278 billion in 2022 and is expected to reach USD 492.12 billion by 2030 and grow at a CAGR of 7.4% over the forecast period of 2023-2030.
The HLA Typing Market size was estimated at USD 1.5 billion in 2022 and is expected to reach USD 2.50 billion by 2030 at a CAGR of 6.6% during the forecast period of 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
